Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Gouty Arthritis (Gout) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Gouty Arthritis (Gout) Overview | 11 | 1 |
| Pipeline Products for Gouty Arthritis (Gout) Comparative Analysis | 12 | 1 |
| Gouty Arthritis (Gout) Therapeutics under Development by Companies | 13 | 2 |
| Gouty Arthritis (Gout) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Gouty Arthritis (Gout) Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Gouty Arthritis (Gout) Products under Development by Companies | 20 | 2 |
| Gouty Arthritis (Gout) Products under Investigation by Universities/Institutes | 22 | 1 |
| Gouty Arthritis (Gout) Companies Involved in Therapeutics Development | 23 | 19 |
| Allena Pharmaceuticals, Inc. | 23 | 1 |
| AstraZeneca Plc | 24 | 1 |
| C&C Research Laboratories | 25 | 1 |
| Cell Medica Limited | 26 | 1 |
| Immune Response BioPharma, Inc. | 27 | 1 |
| IOmet Pharma | 28 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 29 | 1 |
| LG Life Science LTD. | 30 | 1 |
| Monosol Rx LLC | 31 | 1 |
| Nimbus Therapeutics, LLC | 32 | 1 |
| Opsona Therapeutics Limited | 33 | 1 |
| Polaris Pharmaceuticals, Inc. | 34 | 1 |
| ProteoThera, Inc. | 35 | 1 |
| Selvita S.A. | 36 | 1 |
| Swedish Orphan Biovitrum AB | 37 | 1 |
| Teijin Pharma Limited | 38 | 1 |
| TWi Pharmaceuticals, Inc. | 39 | 1 |
| Wellstat Therapeutics Corporation | 40 | 1 |
| XL-protein GmbH | 41 | 1 |
| Gouty Arthritis (Gout) Therapeutics Assessment | 42 | 9 |
| Assessment by Monotherapy Products | 42 | 1 |
| Assessment by Target | 43 | 2 |
| Assessment by Mechanism of Action | 45 | 2 |
| Assessment by Route of Administration | 47 | 2 |
| Assessment by Molecule Type | 49 | 2 |
| Drug Profiles | 51 | 39 |
| ALLN-346 Drug Profile | 51 | 1 |
| anakinra Drug Profile | 52 | 2 |
| APP-112 Drug Profile | 54 | 1 |
| AQB-565 Drug Profile | 55 | 1 |
| AXIBU-03 Drug Profile | 56 | 1 |
| colchicine Drug Profile | 57 | 1 |
| diacerein Drug Profile | 58 | 3 |
| DLX-2323 Drug Profile | 61 | 1 |
| DLX-2681 Drug Profile | 62 | 1 |
| febuxostat Drug Profile | 63 | 2 |
| IR-888 Drug Profile | 65 | 1 |
| LC-350189 Drug Profile | 66 | 1 |
| Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections Drug Profile | 67 | 1 |
| ND-2110 Drug Profile | 68 | 1 |
| ND-2158 Drug Profile | 69 | 1 |
| ND-346 Drug Profile | 70 | 1 |
| pegadricase Drug Profile | 71 | 2 |
| PRT-1000 Drug Profile | 73 | 1 |
| Recombinant Enzyme for Gout and Tumor Lysis Syndrome Drug Profile | 74 | 1 |
| REV-002 Drug Profile | 75 | 1 |
| RLBN-1001 Drug Profile | 76 | 1 |
| SEL-212 Drug Profile | 77 | 1 |
| SHR-4640 Drug Profile | 78 | 1 |
| Small Molecule Inflammasome Modulator Programme Drug Profile | 79 | 1 |
| Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia Drug Profile | 80 | 1 |
| Small Molecules to Inhibit GLUT9 for Gout Drug Profile | 81 | 1 |
| TMX-049 Drug Profile | 82 | 1 |
| URC-102 Drug Profile | 83 | 1 |
| uriSHELS Drug Profile | 84 | 1 |
| verinurad Drug Profile | 85 | 1 |
| WT-2107 Drug Profile | 86 | 1 |
| XEN-102 Drug Profile | 87 | 1 |
| XEN-104 Drug Profile | 88 | 1 |
| XL-400 Drug Profile | 89 | 1 |
| Gouty Arthritis (Gout) Dormant Projects | 90 | 3 |
| Gouty Arthritis (Gout) Discontinued Products | 93 | 1 |
| Gouty Arthritis (Gout) Product Development Milestones | 94 | 10 |
| Featured News &Press Releases | 94 | 1 |
| Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout | 94 | 1 |
| Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment | 95 | 1 |
| May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update | 95 | 1 |
| Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra) | 96 | 1 |
| Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra) | 96 | 1 |
| Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients | 97 | 1 |
| Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout | 98 | 1 |
| Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery | 99 | 1 |
| Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares | 99 | 1 |
| Jun 30, 2015: New Indication for Teijin Pharma s Febuxostat in Europe | 100 | 1 |
| Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout | 101 | 1 |
| Feb 27, 2015: Stiris Research Awarded a Phase IIa Trial in Gout | 101 | 1 |
| Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease | 101 | 1 |
| Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan | 102 | 1 |
| Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout | 102 | 2 |
| Appendix | 104 | 2 |
| Methodology | 104 | 1 |
| Coverage | 104 | 1 |
| Secondary Research | 104 | 1 |
| Primary Research | 104 | 1 |
| Expert Panel Validation | 104 | 1 |
| Contact Us | 104 | 1 |
| Disclaimer | 105 | 1 |
